Teleflex Incorporated has published its 2025 Global Impact Report, outlining recent accomplishments and future plans for its Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and the Taskforce on Climate-related Financial Disclosures (TCFD). The document details progress across four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.

Cam Hicks, Corporate Vice President and Chief Human Resources Officer at Teleflex, emphasized the report's significance. "This year’s Global Impact Report reflects the role Teleflex plays beyond doing business. It showcases the important and tangible impact we’re making in communities, for our environment, and for our people," said Hicks, who also chairs the CSR Steering Committee.

Environmental and Climate Milestones

The report highlights several key environmental achievements since 2019. Teleflex conducted a Physical Climate Risk Assessment to better understand its exposure to physical climate hazards across operations and supply chains. Additionally, the company reported reductions in several key environmental metrics.

Strategic Health Initiatives

Beyond environmental goals, Teleflex introduced a new Global Health Equity Statement. This statement reflects the company's objective to enable a greater number of individuals to reach their full health potential. The full report is available on the company's website.

Teleflex Incorporated has begun enrollment in the global BIOMAG-III Study, a landmark clinical trial evaluating the Freesolve Resorbable Magnesium Scaffold (RMS). The study aims to generate pivotal evidence required to support future regulatory applications for the technology, which is designed to resorb within 12 months and potentially reduce long-term events associated with permanent metallic implants. The trial represents the most comprehensive planned clinical evaluation of Freesolve RMS to date.

Trial Design and Scope

The BIOMAG-III Study is a randomized controlled trial (RCT) designed to compare Freesolve RMS to Xience Drug-Eluting Stent (DES) with respect to Target Lesion Failure (TLF) rate at 12 months. The study plans to enroll 1,859 patients across up to 120 sites worldwide, including up to 60 sites in the United States. The trial will include scaffold lengths up to 40mm.

Clinical Milestones and Data

The initiation of the BIOMAG-III Study follows the recent completion of enrollment in the BIOMAG-II Study, which finished ahead of schedule. That study enrolled 1,861 patients across 20 countries in Europe and Asia Pacific and is also a prospective, international, multi-center RCT comparing Freesolve RMS with Xience DES regarding TLF rate at 12 months.

Additionally, Teleflex recently reported positive long-term data from the BIOMAG-I First-In-Human (FIH) Study. The results demonstrated a 3.5% TLF at four years and showed no new clinical events between the two-year and four-year marks for Freesolve RMS.

Expert Perspectives

Dr. Ron Waksman, Associate Director of Cardiology at MedStar Washington Hospital Center and Chairman of the steering committee for the BIOMAG-III Study, emphasized the importance of the research. "Contributing to this important international study is the first step towards potentially changing how we treat narrowed arteries," he stated. Dr. Itsik Ben-Dor of MedStar Health in Washington, D.C., became the first implanter in the United States for the IDE trial.

Dr. David E. Kandzari, U.S. National Principal Investigator for the BIOMAG-III Study and Chief Scientific Officer at Piedmont Healthcare, noted the technology's potential. "Freesolve RMS technology has shown positive outcomes in the BIOMAG-I FIH trial, with a plateauing of clinical events after resorption," he said.